Share

Profile & Fundamentals

Lonza Group Profile & Fundamentals

Name: Lonza Group financial chart data preview
Creator: iPulse AI
License: https://ipulseai.com/terms

Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.

Interactive annual & quarterly chartsAI financial reviewsReported source tables

Explore this pageJump to a Profile & Fundamentals section

Explore this research

Profile & Fundamentals contents

Jump directly to any section

Company and Market Context

Company Profile & Ownership

Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.

Company profile record

Lonza Group AG

Common Stock · Health Care · Biotechnology

Official website

Company

Company / asset: Lonza Group AG
Security type: Common Stock
Sector: Health Care
Industry: Biotechnology
HQ: 🇨🇭 Switzerland
Head office: Muenchensteinerstrasse 38, Basel, Switzerland, 4002

Leadership & scale

Chief executive: Dr. Wolfgang Wienand Ph.D.
CEO year born: 1972
Full-time employees: 20.1K
Fiscal year end: December

Fundamentals snapshot

Updated 2026-09-14

Market Cap: CHF 38.2B
P/E: 61.3x
Revenue (Q2 26): CHF 3.4B
Profit (Q2 26): CHF 591.0M
Dividend Yield: 0.9%
Revenue (FY 25): CHF 6.5B
Shares in public float: 69.7M
Insider ownership: 0.09%

Reporting & identifiers

Symbol: LONN.SIX
Listing: 🇨🇭 Switzerland | Dividend Tax: 35%
Ticker Currency: CHF
Income Statement Currency: CHF
Balance Sheet Currency: CHF
Cash Flow Currency: CHF
EPS Currency: CHF
Contract Type: SPOT
ISIN: CH0013841017
Asset ID: equity_84fa1055-5544-5b95-ab2c-1dcbae92f9ab

Ownership

Shares Outstanding

Shares outstanding

Annual reported shares outstanding. Values in shares.

Earnings, Profitability & Valuation

Earnings & Revenue

AI Review

The company's recent financial reports show a temporary drop in profits, including a large net loss at the end of 2025. However, this drop is mostly a backward-looking accounting distortion caused by one-time charges from selling off a lower-margin business and restructuring. Underneath this temporary noise, the core business is actually growing steadily. While current free cash flow is negative because the company is spending heavily to build massive new factories, this is a temporary phase. Most reports agree that as these new facilities start running and taking on contracts, earnings will bounce back strongly. There is some disagreement on how quickly this turnaround will happen, but the overall future outlook is highly positive as the company transitions into a highly focused, high-margin business.

Revenue, Net Income, and Free Cash Flow

Revenue
Free cash flow
Net income

Annual reported financial results, converted using the statement's recorded USD conversion. Missing values are omitted. Values in USD.

Valuation

Historical P/E Ratio

Published P/E

Published valuation snapshots. Trailing four-quarter earnings where available; annual earnings otherwise. Non-positive earnings are omitted. Values in times earnings.

Profitability & Margins

AI Review

The company's core profit margins remain highly robust, supported by strong pricing power and a shift toward complex, high-value biological medicines. Although recent look temporarily depressed on paper due to heavy depreciation and one-time restructuring costs, this is an optical illusion. As the company completes the sale of its lower-margin capsules division, its overall profit profile will structurally improve. The main point of agreement is that will expand significantly as newly built factories reach high utilization rates. While there is some minor disagreement on how much near-term energy inflation and labor costs in Western countries will drag on margins, the company's ability to pass these costs onto its clients ensures that its long-term profitability remains highly secure.

Profitability Margins

Gross margin
Operating margin
Net margin
Free cash flow margin

Annual gross, operating, net income and free cash flow divided by revenue for matching reporting dates. Values in percent.

Complete Research Workspace

Unlock the complete Profile & Fundamentals

Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.

Sign in to check access View Base plan

Paywalled preview begins: Reported Data Tables — chart preview

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Reported Data Tables — chart preview

The following tables contain the same values as the financial charts above. Monetary values are USD; margins are percentages. Missing inputs are not estimated. Use is subject to the iPulse AI Terms of Service and applicable source rights.

Source: eodhd. Statement snapshots with chart transformations and ratios calculated by iPulse AI. Snapshot retrieved 2026-09-15.

Annual earnings and profitability
Period end	Revenue	Free cash flow	Net income	Gross margin	Operating margin	Net margin	Free cash flow margin
2016-12-31	4,050,980,392.16	389,215,686.27	295,098,039.22	34.56	13.21	7.28	9.61
2017-12-31	4,669,404,517.45	432,238,193.02	725,872,689.94	35.82	15.13	15.55	9.26
2018-12-31	5,643,584,521.38	564,154,786.15	569,246,435.85	36.41	17.07	10.09	10
2019-12-31	4,346,074,380.17	184,917,355.37	780,991,735.54	38.53	20.13	17.97	4.25
2020-12-31	5,093,785,310.73	177,401,129.94	981,920,903.95	37.84	20.79	19.28	3.48
2021-12-31	5,930,921,052.63	-135,964,912.28	3,228,070,175.44	36.4	15.14	54.43	-2.29
2022-12-31	6,727,567,567.57	-921,081,081.08	1,313,513,513.51	36.96	21.68	19.52	-13.69
2023-12-31	7,977,434,679.33	-312,351,543.94	776,722,090.26	27.04	12.71	9.74	-3.92
2024-12-31	6,041,896,361.63	-157,662,624.04	701,212,789.42	35.99	19.93	11.61	-2.61
2025-12-31	8,235,813,366.96	-257,250,945.78	-346,784,363.18	35.25	21.16	-4.21	-3.12

Published valuation snapshots
Period end	P/E (times earnings)	Earnings basis
2025-12-31	104.55	Trailing four quarters
2024-12-31	30.79	Trailing four quarters
2023-12-31	12.17	Trailing four quarters
2022-12-31	27.71	Annual net income
2021-12-31	19.27	Annual net income

Shares outstanding — chart values
Reporting date	Shares outstanding
2017-01-01	68,460,200
2018-01-01	74,614,700
2019-01-01	74,597,200
2020-01-01	74,811,800
2021-01-01	74,484,900
2022-01-01	74,306,200
2023-01-01	72,700,700
2024-01-01	74,119,700
2025-01-01	70,181,200
2026-01-01	69,940,800

End of the paywalled preview

The excerpt from Reported Data Tables — chart preview to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Earnings, Profitability & Valuation
- Complete profitability ratios
- EPS history and estimate comparisons
- Execution vs expectations
- Annual and quarterly financial views
Capital Expenditure & R&D
- Capital allocation AI review
- Annual capital expenditure
- Investment intensity trends
- Capex and R&D intensity indicators
Balance Sheet
- Balance sheet AI review
- Assets, debt and equity
- Capital structure
- Liquidity and leverage
- Retained earnings
Dividends & Actions
- Cash dividends paid
- Dividend indicators
- Buybacks and issuance
- Combined shareholder returns
- Available corporate actions

Explore complete public research examples

These public assets show the complete asset profiles, fundamental datasets and analysis. Their findings concern those assets, not this report.